| 212.12 -4.24 (-1.96%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 267.02 | 1-year : | 292 |
| Resists | First : | 228.61 | Second : | 250 |
| Pivot price | 213.31  |
|||
| Supports | First : | 194.02 | Second : | 161.42 |
| MAs | MA(5) : | 212.29  |
MA(20) : | 219.51 |
| MA(100) : | 214.12 |
MA(250) : | 178.89 |
|
| MACD | MACD : | -5.7 |
Signal : | -5.9 |
| %K %D | K(14,3) : | 46.9 |
D(3) : | 41.8 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 256.35 | Low : | 125.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NTRA ] has closed above bottom band by 46.9%. Bollinger Bands are 24.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 218.38 - 219.49 | 219.49 - 220.35 |
| Low: | 206.03 - 207.18 | 207.18 - 208.05 |
| Close: | 210.3 - 212.23 | 212.23 - 213.71 |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Fri, 20 Feb 2026
Vanguard Group Inc. Sells 287,620 Shares of Natera, Inc. $NTRA - MarketBeat
Fri, 20 Feb 2026
Cibc World Market Inc. Sells 6,191 Shares of Natera, Inc. $NTRA - MarketBeat
Tue, 17 Feb 2026
Zweig DiMenna Associates LLC Buys 8,400 Shares of Natera, Inc. $NTRA - MarketBeat
Mon, 16 Feb 2026
Natera's Signatera test to be covered under Medicare - MSN
Mon, 16 Feb 2026
Natera, Inc. (NTRA) Stock Analysis: Unpacking the 24.72% Potential Upside in the Diagnostics Powerhouse - DirectorsTalk Interviews
Wed, 04 Feb 2026
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 139 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 94.5 (%) |
| Shares Short | 3,460 (K) |
| Shares Short P.Month | 3,400 (K) |
| EPS | -2.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.1 |
| Profit Margin | -14.7 % |
| Operating Margin | -16.5 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -29.1 % |
| Qtrly Rev. Growth | 34.7 % |
| Gross Profit (p.s.) | 9.68 |
| Sales Per Share | 15.2 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 194 (M) |
| Levered Free Cash Flow | 181 (M) |
| PE Ratio | -92.63 |
| PEG Ratio | 0 |
| Price to Book value | 23.3 |
| Price to Sales | 13.95 |
| Price to Cash Flow | 152.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|